Premium
Variations in the fate of triamterene
Author(s) -
Pruitt Albert W.,
Winkel Joan S.,
Dayton Peter G.
Publication year - 1977
Publication title -
clinical pharmacology and therapeutics
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.941
H-Index - 188
eISSN - 1532-6535
pISSN - 0009-9236
DOI - 10.1002/cpt1977215610
Subject(s) - triamterene , metabolite , drug , chemistry , urine , pharmacokinetics , pharmacology , diuretic , excretion , drug metabolism , absorption (acoustics) , oral administration , metabolism , medicine , biochemistry , hydrochlorothiazide , physics , blood pressure , acoustics
Triamterene is a pteridine used therapeutically as a diuretic. In order to better understand variations in effect and toxicity of triamterene in individuals, the fate of the drug in man was investigated. Both nonradioactive and 14 C‐labeled forms of the drug were administered, and specific methods of analysis were used to separate the parent compoundJrom its metabolite. Individual variation in absorption, binding, and elimination was noted. The drug was excreted in bile as well as urine. Rapid and extensive metabolism of the agent occurred after oral and intravenous doses in healthy adult men. The peak plasma levels of the drug after an oral dose (200 mg) were under 0.3 µg/ml, but the concentration of the primary metabolite (2,4,7‐triamino‐6‐p‐hydroxyphenylpteridine) was higher. The urinary excretion of the metabolite was at least three times that of the parent drug.